The purpose of SMA Europe is to provide a framework to stimulate collaboration and accelerate translational research pathways in SMA and promote patient care.

  1. SMA Europe awards new research grants through its 8th call for research proposals

    SMA research receives vital funds from SMA Europe. Based on the recommendations received by its Scientific Advisory Board, SMA Europe awarded a total of 473,000 Euros to 5 cutting-edge SMA research projects through its 8th Call for Research Proposals. The Scientific Advisory Board reviewed and scored 18 very high level SMA research proposals. As only […]


  2. Novartis provides update on LMI070 and its clinical development

    Novartis provides update on LMI070, a potential treatment for SMA Type 1, through the statement below: “We have made the difficult decision to pause enrollment for our study of LMI070 for the treatment of Type 1 Spinal Muscular Atrophy (SMA). Animal safety studies were taking place in parallel with this trial, which is a common […]


  3. Biogen & Ionis Pharmaceuticals Community Statement

    January 14, 2016 Dear members of the SMA community, In response to further requests for information, we want to provide an update on our investigational program to you and the many families around the world who are touched by SMA. Since our last community post, we have made important progress in moving the compound development […]


  4. Roche announces new clinical trial for RG7916 in spinal muscular atrophy

    Roche, along with partners PTC Therapeutics and the SMA Foundation in the US, recently provided an update on the development of RG7800 and announced a new clinical trial planned for RG7916. The study will take place in The Netherlands. RG7916 is another SMN2 splicing modifier. This new investigational medicine will now advance to its very first clinical […]